New Yorker: Pfizer-Allergan merger a 'disgrace'

Michael Walter | | Health Exec | Management

Pharmaceutical company Pfizer made headlines on Nov. 23 when it announced its plan to buy Ireland-based Allergan for approximately $160 billion.  

John Cassidy of The New Yorker wrote about the big news, pointing out that it is widely acknowledged that the deal is primarily to help Pfizer avoid paying the U.S. corporate tax rate. Cassidy wrote at length on the subject, describing the potential merger as “nothing short of a disgrace.”

“Drug companies like Pfizer have long benefitted from taxpayer-funded research carried out under the auspices of organizations like the National Institutes of Health and the National Science Foundation,” Cassidy wrote. “Now, Pfizer is seeking to avoid paying the taxes that are due on its profits, particularly profits generated by its overseas subsidiaries. Even though the Obama Administration doesn’t have the legal powers to block the Allergan transaction, it should seek to shame Pfizer and its board of directors into calling it off.”

Click below to The New Yorker’s website and read the full text. 

The Pfizer–Allergan Merger Is a Disgrace

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Related Content

Asante Medical facing $488M in lawsuits after fentanyl diversion linked to 16 deaths
FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS
FDA issues Class I recall of infusion pump batteries due to risk of burns
Ransomware group deploys ticking clock to threaten Georgia hospital
Private equity transactions in healthcare down 15% since 2023, report finds

Around the web

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

Cardiovascular Business
FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."